Skip to main content
Terug
WAT logo

Waters Corporation

Datakwaliteit: 100%
WAT
NYSE Healthcare Medical - Diagnostics & Research
€ 301,92
▲ € 0,11 (0,04%)
Marktkapitalisatie: 17,97B
Dagbereik
€ 295,90 € 305,39
52-Weeksbereik
€ 275,05 € 414,15
Volume
507.303
50D / 200D Gem.
€ 344,13 / € 339,49
Vorige Slotkoers
€ 301,81

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (627 peers)

Metriek Aandeel Sector Mediaan
P/E 28,0 0,3
P/B 7,0 2,9
ROE % 29,3 3,7
Net Margin % 20,3 3,8
Rev Growth 5Y % 3,2 10,0
D/E 0,6 0,2

Koersdoel Analisten

Hold
€ 401,00 +32.8%
Low: € 350,00 High: € 480,00
Forward K/W
21,0
Forward WPA
€ 14,38
WPA Groei (sch.)
+0,0%
Omzet Sch.
6,4 B

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2030 € 21,59
€ 21,03 – € 21,98
8,3 B 1
FY2029 € 20,27
€ 19,75 – € 20,63
8 B 1
FY2028 € 17,87
€ 16,68 – € 19,62
7,5 B 3

Belangrijkste Punten

Revenue grew 3,24% annually over 5 years — modest growth
ROE of 29,28% indicates high profitability
Net margin of 20,30% shows strong profitability
Generating 539,81M in free cash flow
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 3,75%
Cash machine — converts 84,00% of earnings into free cash flow

Groei

Revenue Growth (5Y)
3,24%
Revenue (1Y)6,99%
Earnings (1Y)0,75%
FCF Growth (3Y)10,49%

Kwaliteit

Return on Equity
29,28%
ROIC16,88%
Net Margin20,30%
Op. Margin28,22%

Veiligheid

Debt / Equity
0,55
Current RatioN/A
Interest Coverage17,59

Waardering

P/E Ratio
27,96
P/B Ratio7,01
EV/EBITDA21,03
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 6,99% Revenue Growth (3Y) 3,47%
Earnings Growth (1Y) 0,75% Earnings Growth (3Y) 0,03%
Revenue Growth (5Y) 3,24% Earnings Growth (5Y) -1,86%
Profitability
Revenue (TTM) 3,17B Net Income (TTM) 642,63M
ROE 29,28% ROA 12,64%
Gross Margin 57,77% Operating Margin 28,22%
Net Margin 20,30% Free Cash Flow (TTM) 539,81M
ROIC 16,88% FCF Growth (3Y) 10,49%
Safety
Debt / Equity 0,55 Current Ratio N/A
Interest Coverage 17,59 Dividend Yield 0,00%
Valuation
P/E Ratio 27,96 P/B Ratio 7,01
P/S Ratio 5,68 PEG Ratio 75,62
EV/EBITDA 21,03 Dividend Yield 0,00%
Market Cap 17,97B Enterprise Value 18,79B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 3,17B 2,96B 2,96B 2,97B 2,79B
Net Income 642,63M 637,83M 642,23M 707,76M 692,84M
EPS (Diluted) 10,76 10,71 10,84 11,73 11,17
Gross Profit 1,83B 1,76B 1,76B 1,72B 1,63B
Operating Income 893,22M 826,35M 817,68M 873,40M 821,71M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 5,08B 4,55B 4,63B 3,28B 3,09B
Total Liabilities 2,52B 2,73B 3,48B 2,78B 2,73B
Shareholders' Equity 2,56B 1,83B 1,15B 504,49M 367,55M
Total Debt 1,41B 1,70B 2,44B 1,66B 1,60B
Cash & Equivalents 587,83M 324,42M 395,08M 480,53M 501,23M
Current Assets 1,99B 1,67B 1,75B 1,76B 1,63B
Current Liabilities 0,0 789,76M 789,58M 785,74M 680,51M

Strategiescores

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches
#999 of 1052
18

Recente Activiteit

Ingestapt Cash Flow Compounder
Mar 24, 2026